Evidence map›Paper›PMID 38214037›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2024

An Introduction and Practical Guide to Strategies for Analyzing Longitudinal Data in Clinical Trials of Smoking Cessation Treatment: Beyond Dichotomous Point-Prevalence Outcomes.

George Kypriotakis, Steven L Bernstein, Krysten W Bold, James D Dziura, Donald Hedeker, Robin J Mermelstein, Andrea H Weinberger

Open access · bronzeAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

George KypriotakisDepartment of Behavioral Science, UT MD Anderson Cancer Center, Houston, TX, USA.
Steven L BernsteinDepartment of Emergency Medicine, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-9964-7036
Krysten W BoldDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-8012-6118
James D DziuraDepartment of Emergency Medicine, Yale University School of Medicine, New Haven, CT, USA.
Donald HedekerDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
Robin J MermelsteinDepartment of Psychology and Institute for Health Research and Policy, University of Illinois Chicago, Chicago, IL, USA.ORCID 0000-0002-8690-1074
Andrea H WeinbergerFerkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.ORCID 0000-0002-7065-1349
Yale University · USAlbert Einstein College of Medicine · USChicago Department of Public Health · USThe University of Texas MD Anderson Cancer Center · USUniversity of Illinois Urbana-Champaign · US

Funding

Testing Relapse Recovery Intervention ComponentsP01CA180945 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI COOK, JESSICA MEGAN · 2014 to 2023
$23.0M
Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-CigarettesU01DA045524 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MERMELSTEIN, ROBIN J. · 2017 to 2023
$1.6M
NCI NIH HHS P01 CA180945NIDA NIH HHS U01 DA045524NIH HHS P01-CA180945
6 · The paper itself

Abstract

Conceptualizing tobacco dependence as a chronic relapsing condition suggests the need to use analytic strategies that reflect that premise. However, clinical trials for smoking cessation typically define the primary endpoint as a measure of abstinence at a single timepoint distal to the intervention, typically 3-12 months. This reinforces the concept of tobacco outcomes as a dichotomous state-one is, or is not, abstinent. Fortunately, there are several approaches available to handle longitudinal data that reflect the relapsing and remitting nature of tobacco use during treatment studies. In this paper, sponsored by the Society for Research on Nicotine and Tobacco's Treatment Research Network, we present an introductory overview of these techniques and their application in smoking cessation clinical trials. Topics discussed include models to examine abstinence outcomes (eg, trajectory models of abstinence, models for transitions in smoking behavior, models for time to event), models that examine reductions in tobacco use, and models to examine joint outcomes (eg, examining changes in the use of more than one tobacco product). Finally, we discuss three additional relevant topics (ie, heterogeneity of effects, handling missing data, and power and sample size) and provide summary information about the type of model that can be used based on the type of data collected and the focus of the study. We encourage investigators to familiarize themselves with these techniques and use them in the analysis of data from clinical trials of smoking cessation treatment. Implications Clinical trials of tobacco dependence treatment typically measure abstinence 3-12 months after participant enrollment. However, because smoking is a chronic relapsing condition, these measures of intervention success may not accurately reflect the common trajectories of tobacco abstinence and relapse. Several analytical techniques facilitate this type of outcome modeling. This paper is meant to be an introduction to these concepts and techniques to the global nicotine and tobacco research community including which techniques can be used for different research questions with visual summaries of which types of models can be used for different types of data and research questions.

Indexed as

Clinical Trials as TopicSmoking CessationHumansLongitudinal StudiesPrevalenceTobacco Use DisorderTreatment Outcome

Identifiers

PMID38214037
PMCPMC11190044
OpenAlexW4390795603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.